Home Cart Sign in  
Chemical Structure| 15722-48-2 Chemical Structure| 15722-48-2

Structure of Olsalazine
CAS No.: 15722-48-2

Chemical Structure| 15722-48-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Olsalazine is a potent inhibitor of macrophage chemotactic LTB4 with an IC50 of 0.39 mM and reduces the synthesis of 5-HETE, 11-HETE, 12-HETE, and 15-HETE in PMNL and MNL, used for ulcerative colitis research with anti-inflammatory activity.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Kang, Changyu ; Kim, Jaejeong ; Jeong, Yeonhee ; Yoo, Jin-Wook ; Jung, Yunjin ;

Abstract: Background/Objectives: In addition to oncological applications, poly(ADP-ribose) polymerase (PARP) inhibitors have potential as anti-inflammatory agents. Colon-targeted delivery of PARP inhibitors has been evaluated as a pharmaceutical strategy to enhance their safety and therapeutic efficacy against gut inflammation. Methods: Colon-targeted PARP inhibitors 5-aminoisoquinoline (5-AIQ) and 3-aminobenzamide (3-AB) were designed and synthesized by azo coupling with salicylic acid (SA), yielding 5-AIQ azo-linked with SA (AQSA) and 3-AB azo-linked with SA (ABSA). Additional conjugation of AQSA with acidic amino acids yielded glutamic acid-conjugated AQSA (AQSA-Glu) and aspartic acid-conjugated AQSA, which further increased the hydrophilicity of AQSA. Results: The distribution coefficients of PARP inhibitors were lowered by chemical modifications, which correlated well with drug permeability via the Caco-2 cell monolayer. All derivatives were effectively converted to their corresponding PARP inhibitors in the cecal contents. Compared with observations in the oral administration of PARP inhibitors, AQSA-Glu and ABSA resulted in the accumulation of much greater amounts of each PARP inhibitor in the cecum. ABSA accumulated mesalazine (5-ASA) in the cecum to a similar extent as sulfasalazine (SSZ), a colon-targeted 5-ASA prodrug. In the DNBS-induced rat colitis model, AQSA-Glu enhanced the anticolitic potency of 5-AIQ. Furthermore, ABSA was more effective against rat colitis than SSZ or AQSA-Glu, and the anticolitic effects of AQSA-Glu were augmented by combined treatment with a colon-targeted 5-ASA prodrug. In addition, the colon-targeted delivery of PARP inhibitors substantially reduced their systemic absorption. Conclusions: Colon-targeted PARP inhibitors may improve the therapeutic and toxicological properties of inhibitors and synergize the anticolitic effects of 5-ASA.

Keywords: poly(ADP-ribose) polymerase inhibitor ; colon-targeted drug delivery ; colitis ; mesalazine ; prodrug

Purchased from AmBeed: ; ; ;

Alternative Products

Product Details of Olsalazine

CAS No. :15722-48-2
Formula : C14H10N2O6
M.W : 302.24
SMILES Code : OC(C=C1)=C(C(O)=O)C=C1/N=N/C2=CC(C(O)=O)=C(O)C=C2
MDL No. :MFCD00602469
InChI Key :QQBDLJCYGRGAKP-UHFFFAOYSA-N
Pubchem ID :22419

Safety of Olsalazine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313

Isoform Comparison

Biological Activity

Description
Olsalazine is a potent inhibitor of macrophage chemotaxis towards leukotriene B4 (LTB4) with an IC50 value of 0.39 mM. It also reduces the synthesis of various hydroxyeicosatetraenoic acids (HETEs), including 5-HETE, 11-HETE, 12-HETE, and 15-HETE in polymorphonuclear leukocytes (PMNL) and mononuclear cells (MNL). Olsalazine is researched primarily for its potential in treating ulcerative colitis due to its anti-inflammatory properties[1].[2].

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.31mL

0.66mL

0.33mL

16.54mL

3.31mL

1.65mL

33.09mL

6.62mL

3.31mL

References

 

Historical Records

Categories